Hospital
Hospital Service District No 2 of Parish of Beauregard State of LA
Hospital Service District No 2 of Parish of Beauregard State of LA was paid $10.53M by Medicaid between Jan 2018 and Dec 2024, across 174 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoHOSPITAL SERVICE DISTRICT NO 2 OF PARISH OF BEAUREGARD STATE OF LA
DERIDDER, LA 70634
DERIDDER, LA 70634
33aNPI1831193499assigned 06/10/2005
33bProvider typeRural Acute Care Hospital
28Total paid$10.53M
24GClaims296,227
24DCodes billed174
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Louisiana
Rank by total paid#6 of 8
Median peer was paid$12.38M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,332 | $1.21M | |
| 2019 | 43,739 | $1.10M | |
| 2020 | 27,714 | $733K | |
| 2021 | 51,351 | $1.40M | |
| 2022 | 56,807 | $2.04M | |
| 2023 | 43,062 | $2.50M | |
| 2024incomplete | 23,222 | $1.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 21,390 | 18,237 | $2.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 18,229 | 16,154 | $1.56M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.0% | 3,038 | 2,665 | $946K |
| 58662 | 4.2% | 962 | 736 | $441K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 503 | 439 | $424K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.6% | 3,787 | 3,164 | $376K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,223 | 1,014 | $293K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.5% | 7,204 | 6,212 | $261K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.3% | 408 | 369 | $243K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 7,858 | 6,635 | $230K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 6,506 | 5,434 | $208K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 7,251 | 1,834 | $187K |
162 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 2,569 | $172K |
| 80053 | Comprehensive metabolic panel | 1.6% | 25,123 | $171K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 1,980 | $158K |
| 59025 | Fetal non-stress test | 1.4% | 1,573 | $144K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 29,636 | $142K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 1,914 | $124K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 271 | $83K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,259 | $73K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,571 | $60K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,404 | $52K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,066 | $51K |
| 80061 | Lipid panel | <1% | 4,454 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,624 | $46K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,632 | $46K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,450 | $40K |
| 80050 | General health panel | <1% | 948 | $39K |
| 80081 | <1% | 540 | $34K | |
| C9399 | Unclassified drugs or biologicals | <1% | 8,948 | $33K |
| 81001 | <1% | 18,343 | $33K | |
| G0378 | Hospital observation service, per hour | <1% | 516 | $32K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 870 | $32K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 986 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,404 | $28K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,551 | $26K |
| 84702 | <1% | 2,865 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,665 | $24K |
| 87581 | <1% | 921 | $24K | |
| 87486 | <1% | 912 | $24K | |
| 84484 | <1% | 3,538 | $22K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 71 | $22K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,339 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 669 | $22K |
| 81025 | <1% | 3,384 | $22K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 694 | $20K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,487 | $18K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,360 | $16K |
| 97161 | <1% | 337 | $16K | |
| 82553 | <1% | 3,101 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 785 | $15K |
| 94760 | <1% | 6,549 | $15K | |
| 73564 | <1% | 216 | $15K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,281 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,077 | $14K |
| 87480 | <1% | 1,006 | $14K | |
| 87510 | <1% | 1,006 | $14K | |
| 82550 | <1% | 3,799 | $13K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 76 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,588 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 987 | $12K |
| 83735 | <1% | 3,332 | $11K | |
| 85730 | <1% | 3,920 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 844 | $11K |
| 72110 | <1% | 155 | $10K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 353 | $9K |
| 85610 | <1% | 4,056 | $9K | |
| 83880 | <1% | 440 | $7K | |
| 80306 | <1% | 675 | $7K | |
| 87088 | <1% | 1,263 | $7K | |
| 87070 | <1% | 879 | $7K | |
| 83690 | <1% | 1,370 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,748 | $7K |
| 72050 | <1% | 88 | $6K | |
| 97597 | <1% | 433 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $5K |
| 82652 | <1% | 373 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 145 | $5K |
| 87631 | <1% | 934 | $5K | |
| 87634 | <1% | 1,198 | $5K | |
| 87660 | <1% | 283 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 113 | $4K |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 920 | $4K |
| 82607 | <1% | 298 | $4K | |
| 74018 | <1% | 137 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 17 | $4K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 28 | $4K |
| 81003 | <1% | 2,515 | $3K | |
| 86592 | <1% | 887 | $3K | |
| 94060 | <1% | 41 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 124 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 71 | $3K |
| 85660 | <1% | 578 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 12 | $2K |
| 84439 | <1% | 298 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 419 | $2K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 17 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 174 | $2K |
| A6453 | Self-adherent bandage, elastic, non-knitted/non-woven, width less than three inches, per yard | <1% | 1,686 | $2K |
| 84481 | <1% | 139 | $2K | |
| 94726 | <1% | 41 | $2K | |
| 80305 | <1% | 165 | $2K | |
| 85651 | <1% | 460 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,732 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 649 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 28 | $1K |
| 94729 | <1% | 41 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 190 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 225 | $1K |
| 86140 | <1% | 305 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 293 | $1K |
| 87807 | <1% | 86 | $1K | |
| 72100 | <1% | 14 | $1K | |
| 87077 | <1% | 197 | $1K | |
| 93041 | <1% | 40 | $978.22 | |
| 73565 | <1% | 33 | $831.32 | |
| 29581 | <1% | 132 | $815.58 | |
| 87150 | <1% | 27 | $807.08 | |
| 84466 | <1% | 72 | $803.88 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,678 | $798.66 |
| 82150 | <1% | 180 | $780.13 | |
| 83540 | <1% | 129 | $764.27 | |
| 82105 | <1% | 48 | $746.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 48 | $577.39 |
| 73502 | <1% | 16 | $559.68 | |
| 73110 | <1% | 16 | $533.00 | |
| 86038 | <1% | 52 | $507.78 | |
| 87186 | <1% | 137 | $506.15 | |
| 87340 | <1% | 72 | $489.29 | |
| 81015 | <1% | 1,950 | $479.66 | |
| 73630 | <1% | 14 | $434.88 | |
| 82043 | <1% | 83 | $433.12 | |
| 82677 | <1% | 19 | $422.81 | |
| 82728 | <1% | 51 | $412.31 | |
| 80299 | <1% | 39 | $410.08 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 808 | $397.13 |
| 83550 | <1% | 137 | $391.96 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $390.66 |
| 84100 | <1% | 87 | $368.40 | |
| 84403 | <1% | 15 | $361.34 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 101 | $355.13 |
| 85379 | <1% | 42 | $346.12 | |
| 86762 | <1% | 36 | $280.76 | |
| 86336 | <1% | 19 | $272.56 | |
| 86431 | <1% | 46 | $232.47 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,013 | $224.56 |
| 84145 | <1% | 15 | $193.26 | |
| 87015 | <1% | 42 | $187.04 | |
| 86850 | <1% | 54 | $183.01 | |
| 87081 | <1% | 27 | $165.19 | |
| 87040 | <1% | 20 | $137.64 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 269 | $112.43 |
| 83605 | <1% | 17 | $104.13 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 120 | $83.58 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 472 | $80.00 |
| 86900 | <1% | 41 | $64.32 | |
| 86901 | <1% | 41 | $64.32 | |
| 84550 | <1% | 15 | $55.37 | |
| 82947 | <1% | 24 | $55.02 | |
| 82950 | <1% | 13 | $49.37 | |
| 36000 | <1% | 120 | $46.05 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 249 | $36.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 150 | $9.44 |
| 84156 | <1% | 22 | $3.67 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 1,325 | $2.39 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 12 | $0.00 |
| 58120 | 0% | 279 | $0.00 | |
| 82570 | 0% | 21 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 49 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 19 | $0.00 |
| 70320 | 0% | 379 | $0.00 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 147 | $0.00 |
| A6455 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to five inches, per yard | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVEILLON, JARRED (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hospital Service District No 2 of Parish of Beauregard State of LA | Deridder, LA | $5.06M |
| Hospital Service District No 2 of Parish of Beauregard State of LA | Deridder, LA | $4.90M |
| Beauregard Memorial Hospital Medical Staff Services | Deridder, LA | $192K |
| Beauregard Physician Group, LLC | Deridder, LA | $804.45 |
| West Louisiana Health Services INC | Deridder, LA | $120.69 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.